• 1. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 2. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244
• 3. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 4. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 5. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200

Introduction to 5-Bromo-3-chloro-1-methylisoquinoline (CAS No. 1215767-97-7)

5-Bromo-3-chloro-1-methylisoquinoline, identified by its Chemical Abstracts Service (CAS) number 1215767-97-7, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical and medicinal chemistry. This compound belongs to the isoquinoline family, a class of nitrogen-containing aromatic organic compounds known for their diverse biological activities and pharmacological properties. The presence of bromine and chlorine substituents at specific positions in its molecular structure enhances its reactivity, making it a valuable intermediate in the synthesis of more complex molecules.

The isoquinoline scaffold is structurally reminiscent of benzene but incorporates a nitrogen atom into the aromatic system, which imparts unique electronic and steric properties. These properties make isoquinoline derivatives attractive candidates for drug discovery, particularly in the development of compounds targeting neurological disorders, infectious diseases, and cancer. The specific substitution pattern in 5-Bromo-3-chloro-1-methylisoquinoline—namely the bromine at the 5-position, chlorine at the 3-position, and a methyl group at the 1-position—provides a versatile platform for further functionalization and derivatization.

In recent years, there has been a surge in research focused on developing novel isoquinoline-based therapeutic agents. The bromine and chlorine atoms in 5-Bromo-3-chloro-1-methylisoquinoline serve as excellent handles for palladium-catalyzed cross-coupling reactions, such as Suzuki-Miyaura, Heck, and Buchwald-Hartwig couplings. These reactions are pivotal in constructing biaryl systems, which are prevalent in many bioactive molecules. For instance, studies have demonstrated that derivatives of this compound can be coupled with aryl halides or boronic acids to generate more complex isoquinoline analogs with enhanced binding affinity to biological targets.

One of the most compelling aspects of 5-Bromo-3-chloro-1-methylisoquinoline is its potential as a precursor to kinase inhibitors. Isoquinoline derivatives have shown promise in inhibiting various kinases involved in cancer progression. The bromine and chlorine substituents facilitate the introduction of additional functional groups that can be tailored to optimize interactions with the active sites of these enzymes. Recent preclinical studies have highlighted the efficacy of certain isoquinoline-based inhibitors in reducing tumor growth and proliferation in vitro and in vivo. The structural features of 5-Bromo-3-chloro-1-methylisoquinoline make it an ideal candidate for further exploration in this context.

The synthesis of 5-Bromo-3-chloro-1-methylisoquinoline typically involves multi-step organic transformations starting from readily available precursors. One common synthetic route begins with the condensation of 3-bromomethylbenzoic acid with methylamine to form 1-methylisoquinoline-3-carboxylic acid. Subsequent bromination at the 5-position using N-bromosuccinimide (NBS) followed by chlorination at the 3-position via chlorination agents like phosphorus oxychloride (POCl?) yields the desired product. This method leverages classical organic chemistry techniques while taking advantage of modern catalytic systems to improve yield and purity.

The role of computational chemistry in optimizing synthetic routes for 5-Bromo-3-chloro-1-methylisoquinoline cannot be overstated. Molecular modeling techniques allow researchers to predict reaction outcomes and identify optimal conditions for synthesis before conducting experimental trials. This approach not only saves time but also reduces waste by minimizing trial-and-error experimentation. Furthermore, computational methods can help elucidate the mechanistic details of transformations involving this compound, providing insights that guide future synthetic endeavors.

From a medicinal chemistry perspective, 5-Bromo-3-chloro-1-methylisoquinoline serves as a building block for exploring structure-activity relationships (SAR). By systematically varying substituents on its scaffold, researchers can gain a deeper understanding of how different functional groups influence biological activity. For example, replacing one halogen atom with another or introducing nitrogen-containing heterocycles can significantly alter binding affinity and selectivity. Such modifications are crucial for developing lead compounds with improved pharmacokinetic profiles and reduced toxicity.

The pharmaceutical industry has shown particular interest in isoquinoline derivatives due to their potential applications beyond oncology. Emerging research indicates that compounds like 5-Bromo-3-chloro-1-methylisoquinoline may have antimicrobial properties, making them candidates for treating drug-resistant infections. Additionally, their ability to cross the blood-brain barrier suggests utility in treating neurodegenerative diseases such as Alzheimer's and Parkinson's. While much of this research is still in its early stages, the versatility of 5-Bromo-3-chloro-1-methylisoquinoline makes it a promising candidate for future therapeutic development.

In conclusion,5-Bromo-3-chloro-1-methylisoquinoline (CAS No. 1215767-97-7) is a multifaceted compound with significant potential in pharmaceutical research. Its unique structural features enable diverse synthetic modifications, making it an invaluable intermediate for drug discovery efforts targeting various diseases. As our understanding of molecular interactions continues to evolve, compounds like this will undoubtedly play an increasingly important role in developing next-generation therapeutics.

• 1206984-59-9(5-Bromo-1-chloro-3-methylisoquinoline)
• 1601098-79-6(6-Bromo-1-chloro-3-methylisoquinoline)
• 1206250-53-4(4-Bromo-2-chloro-6-methylpyridine)
• 869898-11-3(4-bromo-1-chloro-3-methylisoquinoline)
• 2137581-11-2(Isoquinoline, 4-bromo-1-chloro-3,7-dimethyl-)
• 1029720-67-9(5-Bromo-3-chloroisoquinoline)
• 15787-12-9(Isoquinoline, 3-chloro-1-methyl-)
• 1603505-51-6(8-bromo-1-chloro-3-methylisoquinoline)
• 1206980-30-4(Isoquinoline, 7-bromo-1-chloro-3-methyl-)
• 7115-16-4(1-chloro-3-methylisoquinoline)